当前位置： SCI文献检索 > JAPANESE JOURNAL OF CLINICAL ONCOLOGY期刊下所有文献 > A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.

A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.

Abstract：

OBJECTIVE:To assess the resectability rate of patients with initially unresectable liver-only metastases from colorectal cancer (CRC) after treatment with irinotecan/capecitabine. METHODS:Patients received irinotecan (240 mg/m(2)) as a 30 min intravenous infusion on day 1 and capecitabine (1000 mg/m(2)) orally bid for 14 days beginning on day 2. Treatment was repeated every 3 weeks. The protocol encouraged two to four cycles of irinotecan/capecitabine after recovery from surgery. RESULTS:Between May 2004 and February 2007, 48 patients entered in the study. Forty-seven (97.9%) of the 48 patients were assessable for response. The overall response rate before surgery was 56.3% (95% CI, 42.3-70.3%) in the treated population, including 2 non-confirmed complete response (CR), 18 partial responses (PR) and 7 non-confirmed PR. Twenty-three (47.9%) of 29 patients with tumor shrinkage proceeded to surgical intervention. Twenty of the 23 patients had a complete resection (S-CR). With a median follow-up time of 32 months (range, 24-38 months), the overall median time to progression and overall survival for all patients were 16.7 months (95% CI, 10.0-23.4 months) and 27.5 months (95% CI, 23.6-31.4 months) for all patients. The 1- 2- and 3-year overall survival estimates were 79.2% (95% CI, 67.7-90.7%), 60.4% (95% CI, 46.6-74.3%) and 29.2% (95% CI, 16.3-42.0%), respectively. Grade 3 diarrhea occurred in eight (17.0%) patients. The most common Grade 3/4 hematological adverse event was neutropenia in 8.5% of the patients. There were no treatment-related deaths during this study. CONCLUSIONS:Irinotecan/capecitabine appears to be a safe and very effective regimen in selected patients with unresectable liver metastases from CRC, but who are treated with a curative intent.

journal_name

Jpn J Clin Oncol

journal_title

Japanese journal of clinical oncology

authors

Zhao R,Zhu J,Ji X,Cai J,Wan F,Li Q,Zhong B,Tucker S,Wang D

doi

10.1093/jjco/hyp114

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

10-6

issue

eissn

0368-2811

issn

1465-3621

pii

hyp114

journal_volume

pub_type

杂志文章

在线工具

A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.